Investigational drug · Phase 3
Valoctocogene roxaparvovec
Also called: BMN 270, GENEr8
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hemophilia A, Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "Valoctocogene roxaparvovec"
First trial start
2020
Dec 10, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Valoctocogene roxaparvovec", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hemophilia A
- Hemophilia A With Inhibitor
- Hemophilia A With Anti Factor VIII
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Valoctocogene roxaparvovec" as an intervention, largest first.
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)Pivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03370913 · 144 participants · Start Dec 19, 2017 · Primary completion Nov 16, 2020
Drug: valoctocogene roxaparvovec · For: Hemophilia A
Sites: Los Angeles, California; Sacramento, California; San Diego, California · 49 sites in all
- Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia APivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT04323098 · 22 participants · Start Dec 8, 2020 · Primary completion Jan 27, 2023
Drug: valoctocogene roxaparvovec · For: Hemophilia A
Sites: Sacramento, California; St Louis, Missouri; Columbus, Ohio · 12 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT02576795 · 15 participants · Start Sep 28, 2015 · Primary completion Feb 14, 2024
Drug: valoctocogene roxaparvovec · For: Severe Haemophilia A
Sites: Birmingham, United Kingdom; Cambridge, United Kingdom; London, United Kingdom · 5 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT04684940 · 10 participants · Start Dec 10, 2020 · Primary completion Apr 20, 2026
Drug: Valoctocogene roxaparvovec · For: Hemophilia A With Inhibitor; Hemophilia A With Anti Factor VIII
Sites: Los Angeles, California; Campinas, Brazil; Ramat Gan, Israel · 9 sites in all
- Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia APivotal-lookingActive, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT06224907 · 6 participants (planned) · Start Dec 25, 2023 · Primary completion Apr 16, 2025
Drug: Valoctocogene roxaparvovec · For: Hemophilia A
Sites: Hokkaido, Japan; Saitama, Japan; Aichi, Japan · 4 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03520712 · 3 participants · Start Apr 24, 2018 · Primary completion Aug 7, 2024
Drug: Valoctocogene Roxaparvovec · For: Hemophilia A; Gene Therapy; Clotting Disorders and 1 more
Sites: Johannesburg, South Africa; Seoul, South Korea; Kaohsiung City, Taiwan · 9 sites in all
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03392974 · 1 participants · Start Mar 14, 2018 · Primary completion May 22, 2019
Drug: Valoctocogene Roxaparvovec · For: Hemophilia A
Sites: Pittsburgh, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- Future directions and challenges of drug development and non-human primate models.
Wang Z, Wu X · Life Sci 2026
- Patient-Relevant Questions on Gene Therapy for Haemophilia.
Miesbach W, Alberio L, Angelilo-Scherrer A, et al. · Hamostaseologie 2026
- Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.
Afifah NN, Permatasari LI, Latarissa IR, et al. · Haemophilia 2026
- Italian Patients Journey for Gene Therapy in Haemophilia A.
Di Minno G, Spadarella G, Borchiellini A, et al. · Haemophilia 2026
- Arthroplasty After Hemophilia Gene Therapy: Perioperative Implications and Clinical Experience.
Vu DN, Nguyen TT, Pham TN, et al. · Haemophilia 2026
- Impact of Gene Therapy on the Haemophilia-Free Mind: Outcomes Before and After Valoctocogene Roxaparvovec in GENEr8-1 Trial Participants.
Hermans C, Karimi M, Camp C, et al. · Haemophilia 2026
Also in development for Hemophilia A
- SR604Phase 34 trials
Shanghai RAAS Blood Products Co., Ltd. · Factor VII Deficiency, Hemophilia A, Hemophilia B
- BIVV001efanesoctocog, AltuvoctPhase 33 trials
Swedish Orphan Biovitrum · Haemophilia A (Moderate or Severe), Hemophilia A, Hemophilia A, Severe
- GS1191-0445Phase 32 trials
Gritgen Therapeutics Co., Ltd. · Severe Hemophilia A, Hemophilia A
- NXT007Zemocimig, RO7589655Phase 32 trials
Roche (Genentech) · Hemophilia A
- ARD001Phase 21 trial
Arditus Pte Ltd · Hemophilia A, Healthy Adult Participants
- ASC618Phase 21 trial
ASC Therapeutics · Hemophilia A
- BAY2599023DTX201Phase 21 trial
Bayer · Hemophilia A
- SPK-8011QQRO7878488Phase 21 trial
Roche (Genentech) · Hemophilia A
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BioMarin.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.